We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Its segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used... Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Its segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. It provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company distributes its systems through its direct sales force and support organizations. Show more
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024...
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ –...
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ –...
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding...
Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 6.8085106383 | 2.35 | 2.62 | 2.31 | 2814016 | 2.48460657 | CS |
4 | -0.11 | -4.19847328244 | 2.62 | 3.04 | 2.17 | 3120595 | 2.63995943 | CS |
12 | 0.15 | 6.35593220339 | 2.36 | 3.04 | 2.17 | 2350585 | 2.60957679 | CS |
26 | 0.46 | 22.4390243902 | 2.05 | 3.04 | 1.735 | 1773054 | 2.45320726 | CS |
52 | 1.04 | 70.7482993197 | 1.47 | 3.16 | 1.46 | 1083580 | 2.41379861 | CS |
156 | -1.09 | -30.2777777778 | 3.6 | 4.23 | 0.92 | 799052 | 2.23820476 | CS |
260 | -1.09 | -30.2777777778 | 3.6 | 4.23 | 0.92 | 799052 | 2.23820476 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions